Database→SS-31

Tier 1–2MitochondrialCardiacAnti-agingPREMIUM

SS-31

Elamipretide (MTP-131 / Bendavia)

FDA Accelerated Approval 2025 (Barth Syndrome / ELAMINE). Research compound for all other indications. Post-approval confirmatory trials required. Not listed on 2026 WADA Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane to stabilize energy production and reduce oxidative stress. It received FDA accelerated approval in 2025 for Barth syndrome, making it the first treatment ever approved for this cardiolipin disorder. Multiple Phase 2 trials are underway for heart failure, renal disease, and age-related conditions.

🔒

Full Profile: Premium Members Only

The complete SS-31 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use